KazakhstanTuberculosis profile
Population  2014 17 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (1.2–1.8) 8.6 (7–10)
Mortality (HIV+TB only) 0.037 (<0.01–0.11) 0.21 (0.02–0.64)
Prevalence  (includes HIV+TB) 22 (6.5–47) 127 (38–270)
Incidence  (includes HIV+TB) 17 (11–25) 99 (64–141)
Incidence (HIV+TB only) 0.59 (0.38–0.84) 3.4 (2.2–4.8)
         
Case detection, all forms (%) 89 (62–140)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 26 (25–27) 58 (57–59)
MDR-TB cases among notified pulmonary
TB cases
2 600 (2 500–2 700) 2 300 (2 200–2 300)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 8 026   2 414
Pulmonary, clinically diagnosed 1 883   1 050
Extrapulmonary 1 571   300
       
Total new and relapse 15 244    
Previously treated, excluding relapses 474    
Total cases notified 15 718    
Among 15 244 new and relapse cases:
452 (3%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 9 597 (120%) 6 377 (150%) 15 974
Laboratory-confirmed RR-/MDR-TB cases     5 877
Patients started on MDR-TB treatment ***     7 315
TB/HIV 2014 Number (%)
TB patients with known HIV status 15 435 (98)
HIV-positive TB patients 625 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 487 (78)
HIV-positive TB patients on antiretroviral therapy (ART) 472 (76)
HIV-positive people screened for TB 12 446  
HIV-positive people provided with IPT 805  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (89) 14 456
Previously treated cases, excluding relapse, registered in 2013 (63) 464
HIV-positive TB cases, all types, registered in 2013 (59) 340
RR-/MDR-TB cases started on second-line treatment in 2012 (73) 7 213
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.7
Culture (per 5 million population) 24.5
Drug susceptibility testing (per 5 million population) 6.3
Sites performing Xpert MTB/RIF 23
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 195
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-29 Data: www.who.int/tb/data